How PT-141 works: receptors and behavior
The animal experiments make this mechanism interesting. They also make a single, sweeping story about desire unusually hard to defend.
The female rats approached
In Pfaus and colleagues’ female-rat experiment, PT-141 increased solicitation: the animals made more approaches associated with seeking sexual contact. General movement, pacing and lordosis, the mating posture, were unchanged. That selectivity impresses me. The experiment distinguished a particular behavior from several others.
That is animal evidence. A rat approaching a mate cannot describe wanting, disappointment or pleasure in the way a person can. I admire this behavioral precision; a sweeping claim about human intimacy would lose it.
Melanocortin receptors
PT-141 activates melanocortin receptors, chiefly MC4R and also MC3R in the central nervous system. A receptor is a responsive part of a cell; an agonist is something that activates it. The early PT-141 work links this action to hypothalamic neuronal activation in animal experiments and to sexual response. Dopaminergic pathways are a proposed part of the explanation, rather than a fully settled account of how the drug changes desire.
This receptor family reaches beyond sexual response. MC4R also participates in appetite regulation, which helps explain the food-intake and body-weight findings in women given frequent research doses. MC1R activity provides the pigment connection described in the label’s warning about skin and gum darkening. A receptor has several biological jobs, however neatly a medicine is advertised for one of them.
The history of melanocortin peptide therapeutics traces PT-141 to melanotan-II, an earlier peptide explored for tanning. Sexual effects noticed during that work led Palatin Technologies toward development for sexual function. The pigmentation connection has a history as well as a receptor explanation.
Women’s brain scans
A crossover study in 31 premenopausal women with HSDD compared MC4R agonism with placebo. The women reported increased sexual desire for up to 24 hours. During erotic stimuli, the scans showed altered processing, including increased functional connectivity between the amygdala and insula and changes in cerebellar and supplementary-motor activity.
Functional connectivity describes coordinated activity in the scan, rather than a new physical connection between brain regions. The women’s reported desire and the imaging result are different observations. Together they support a central mechanism; neither gives a direct measurement of someone’s pleasure during sex.
Female hamsters and sexual reward
The 2025 female Syrian hamster study found no enhancement of sexual reward in a conditioned-place-preference test. It also found no change in melanocortin-receptor mRNA expression in the mesolimbic dopamine system after either low- or high-dose bremelanotide. These are findings in female hamsters, including a negative behavioral result, rather than clinical results in women.
I welcome this awkward piece of biology. It makes the easy progression from receptor activation to desire to reward look less tidy, and it gives the next experiment a sharper question. Seeking contact and finding it rewarding deserve their own measurements.
Blood flow and testosterone
PDE-5 inhibitors act on vascular smooth muscle to help erectile blood flow; PT-141 acts centrally on sexual-response circuitry. The review of emerging erectile-dysfunction therapies discusses melanocortin agonists in that investigational context, including interest in combining central and peripheral approaches. Male use remains outside the approved indication.
PT-141 does not directly raise testosterone or act as hormone replacement. The clinical trials concern outcomes in a defined population, and the label figures concern a particular finished medicine. A plausible mechanism leaves both of those questions open to their own evidence.